1. Bradshaw C, Nguyen A, Surles J. Date accessed: Oct 28, 1998.

2. United States Pharmacopeial Convention (USP), ed. Hypericum (St. John's wort). Botanical Monograph Series. Rockville: United States Pharmacopeial Convention, 1998.

3. Barnes J, Anderson LA, Phillipson JD. St. John's wort (Hypericumperforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001;53:583-600.

4. Pepping J. Alternative therapies. St. John's wort: Hypericum perforatum. Am J Health Syst Pharm 1999;56:329-330.

5. Bennett DA Jr, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacotherapy 1998;32:1201-1208.

6. Schulz V. Clinical trials with Hypericum extracts in patients with depression-results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine 2002;9:469-474.

7. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression—an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253-258.

8. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's Wort in major depression. JAMA 2001;285(15):1978-1986.

9. Davidson JRT, Gadde KM, Fairbank JA, Krishnan KRR, Califf RM, Binanay C. Effect of Hypericum perforatum (St. John's Wort) in major depressive disorder. JAMA 2002;287(14):1807-1814.

10. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St. John's wort): randomized controlled double blind non-inferiority trial versus paroxetine. BMJ 2005;330:503-508.

11. Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Ther 1999;290(3):1363-1368.

12. Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine, and dopamine involvement in the antidepressant action of Hypericum Perforatum. Pharmacopsychiatry 2001;34:45-49.

13. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum Extract. Pharmacopsychiatry 1998;31(Suppl):16-21.

14. Calapai G, Crupi A, Firenzuoli F, et al. Interleukin-6 involvement in antidepressant action of Hypericum Perforatum. Pharmacopsychiatry 2001;34(Suppl 1):S8-S10.

15. Fiebich BL, Hollig A, Lieb K. Inhibition of substance P-induced cytokine synthesis by St. John's Wort extracts. Pharmacopsychiatry 2001;34(Suppl 1):S26-S28.

16. Kleber E, Obry T, Hippeli S, Schneider W, Elstner EF. Biochemical activities of extracts from Hypericum perforatum L. Drug Res 1999;2:106-109.

17. Raffa R. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals receptor binding. Life Sci 1998;62:PL265-270.

18. Butterweck V, Nahrstedt A, Evans J, et al. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology 2002;162:193-202.

19. Simmen U, Bobirnac I, Ullmer C, et al. Antagonist effect of pseudohypericin at CRFX receptors. Eur J Pharmacol 2003;458:251-256.

20. Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001;68:1593-1605.

21. Kumar V, Jaiswal AK, Singh PN, Bhattacharya SK. Anxiolytic activity of Indian Hypericum perforatum Linn: an experimental study. Indian J Exp Biol 2000;38:36-41.

22. Taylor L, Kobak KA. An open-label trial of St. John's Wort (Hypericumperforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000;61:575-578.

23. Schulz H, Jobert M. Effects of hypericum extract on the sleep EEG in older volunteers. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S39-S43.

24. Volz HP, Murck H, Kasper S, Moller HJ. St. John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002;164:294-300.

25. Schempp CM, Pelz K, Wittmer A, Schopf E, Simon JC. Antibacterial activity of hyperforin from St. John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet 1999;353:2129.

26. Liebes L, Mazur Y, Freeman D, et al. A method for the quantification of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 1991;195:77-85.

27. Lavie G, Valentine F, Levin B, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci USA 1989;86:5963-5967.

28. Taher MM, Lammering GM, Hershey CM, Valerie KC. Mood-enhancing antidepressant St. John's Wort inhibits the activation of human immunodeficiency virus gene expression by ultraviolet light. Life 2002;54:357-364.

29. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, for the AIDS Clinical Trials Group 150 and 258 Protocol Teams. Phase I studies of hypericin, the active compound in St. John's wort, as an antiretroviral agent in HIV-infected adults. Ann Intern Med 1999;130:510-514.

30. Okpanyi SN, Lidzba H, Scholl BC, Miltenburger HG. Genotoxicity of a standardized hypericum extract. Arzneimittelforschung 1990;40:851-855.

31. Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John's wort has no effect on pain in polyneuropathy. Pain 2000;91:361-365.

32. Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002;64:1767-1775.

33. Tedeschi E, Menegazzi M, Margotto D, Suzuki H, Forstermann U, Kleinert H. Antiinflammatory actions of St. John's Wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of tran-scription-a (STAT-1a) activation. J Pharmacol Exp Ther 2003;307:254-261.

34. Schempp CM, Windeck T, Hezel S, Simon JC. Topical treatment of atopic dermatitis with St. John's wort cream—a randomized, placebo controlled, double blind half-sided comparison. Phytomedicine 2003;10(Suppl IV):31-37.

35. Hunt EJ, Lester CE, Lester EA, Tackett RL. Effect of St. John's wort on free radical production. Life Sci 2001;69:181-190.

36. Stevinson C, Ernst E. A pilor study of Hypericum perforatum for the treatment of premenstrual syndrome. Br J Obstet Gynaecol 2000;107:870-876.

37. Orellana C. St. John's Wort helps to fight bladder cancer. Lancet Oncol 2001;2:399.

38. Hostanska K, Bommer S, Weber M, Krasniqi B, Saller R. Comparison of the growth-inhibitory effect of Hypericum perforatum L. extracts, differing in the concentration of phloroglucinols and flavonoids, on leukaemia cells. J Pharm Pharmacol 2003;55:973-980.

39. Roscetti G, Franzese O, Comandini A, Bonmassar E. Cytotoxic activity of Hyperi-cum perforatum L. on K562 erythroleukemic cells: differential effects between methanolic extract and hypericin. Phytother Res 2004;18:66-72.

40. Kimura H, Harris MS, Sakamoto T, et al. Hypericin inhibits choroidal endothelial cell proliferation and cord formation in vitro. Curr Eye Res 1997;16:967-972.

41. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of Hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S47-S53.

42. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996;40:2087-2193.

43. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001;8(2):152-160.

44. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998;54:589-594.

45. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and Pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30(Suppl):94-101.

46. Holme SA, Roberts DL. Erythroderma associated with St. John's wort. Brit J Dermatol 2000;143:1097-1131.

47. Sultana D, Peindl KS, Wisner KL. Rash associated with St. John's Wort treatment in premenstrual dysphoric disorder. Arch Womens Ment Health 2000;3:99-101.

48. Lane-Brown MM. Photosensitivity associated with herbal preparations of St. John's wort (Hypericum perforatum). Med J Aust 2000;172:302.

49. Schempp CM, Muller K. Single-dose and steady-state administration of Hypericum perforatum extract (St. John's Wort) does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation. Arch Dermatol 2001;137:512-513.

50. Roberts JE, Wang RH, Tan IP, Datillo M, Chignell CF. Hypericin (active ingredient in St. John's Wort) photooxidation of lens proteins. Abstracts of the 27th Annual Meeting of the American Society of Photobiology 1999;42S.

51. Laird RD, Webb M. Psychotic episode during use of St. John's wort. J Herb Pharmacother 2001;1(2):81-87.

52. Parker V, Wong AHC, Boon HS, Seeman MV. Adverse reactions to St. John's Wort. Can J Psych 2001;46(1):77-79.

53. Brown TM. Acute St. John's Wort toxicity. Am J Emerg Med 2000;18(2):231-232.

54. Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's Wort. Am J Med 2002;112:507-508.

55. Lantz MS, Buchalter E, Giambanco V. St. John's Wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999;12:7-10.

56. Gordon JB. SSRIs and St. John's Wort: possible toxicity? Am Fam Physician 1998;57(5):952-953.

57. Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John's Wort. Soc Biol Psych 1999;46:1707-1708.

58. Moses EL, Mallinger AG. St. John's Wort: three cases of possible mania induction. J Clin Psychopharmacol 2000;20(1):115-117.

59. Dean AJ. Suspected withdrawal syndrome after cessation of St. John's wort. Ann Pharmacother 2003;37:150.

60. Ferko N, Levine MAH. Evaluation of the association between St. John's Wort and elevated thyroid-stimulating hormone. Pharmacotherapy 2001;21(12):1574-1578.

61. Bhopal JS. St. John's Wort-induced sexual dysfunction. Can J Psych 2001;46(5):456-457.

62. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's Wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66(9):133-139.

63. Roby CA, Dryer DA, Burstein AH. St. John's Wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001;21(5):530-532.

64. Wenk M, Todesco L, Krahenbuhl S. Effect of St. John's Wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004;57(4):495-499.

65. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St. John's wort (Hypericumperforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001:317-326.

66. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St. John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67(5):451-457.

67. Peebles KA, Baker RK, Kurz EU, Schneider BJ, Kroll DJ. Catalytic inhibition of human DNA topoisomerase IIa by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum). Biochem Pharmacol 2001;62:1059-1070.

68. Wentworth M, Agostini M, Love J, Schwabe JW, Chatterjee VKK. St. John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000;166:R11-R16.

69. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97(13):7500-7502.

70. Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004;32(5):512-518.

71. Wang E, Barecki-Roach M, Johnson WW. Quantitative characterization of direct P-glycoprotein inhibition by St. John's wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004;56:123-128.

72. Izzo AA. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004;42(3):139-148.

73. Hennessy M, Kelleher D, Spiers JP, et al. St. John's wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82.

74. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's Wort and cyclosporine. Ann Pharmacotherapy 2000;34:1013-1016.

75. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355:548-549.

76. Breidenbach TH, Hoffmann MW, Becker TH, Schlitt H, Klempnauer J. Drug interaction of St. John's wort with ciclosporin. Lancet 2000;355:1912.

77. Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporine. Int J Clin Pharmacol Ther 2000;38(10):500-502.

78. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John's Wort) after organ transplantation. Am J Kidney Dis 2001;38(5):1105-1107.

79. Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M. Unexplained decrease of cyclosporine trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000;15:1473-1474.

80. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St. John's wort) with cyclosporine A metabolism in a patient after liver transplantation. J Hepatol 2000;33:853-855.

81. Mai I, Stürmer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18(4):819-822.

82. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St. John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56(6):683-690.

83. Gorski JC, Hamman MA, Wang Z, Vasavada N, Huang S, Hall SD. The Effect of St. John's Wort on the efficacy of oral contraception. Clin Pharmacol Ther;71(2):P25.

84. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-549.

85. de Maat MMR, Hoetelmans RMW, Mathot RAA, et al. Drug interactions between St. John's wort and nevirapine. AIDS 2001;15(3):420-421.

86. Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-term St. John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78(1):25-33.

87. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John's Wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24(11):1508-1514.

88. Crowe S, McKeating K. Delayed emergence and St. John's Wort. J Am Soc Anesth 2002;9(4):1025-1027.

89. Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John's Wort. J Clin Anesth 2000;12:498-499.

90. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66(4):338-345.

91. Xie HG, Kim RB. St. John's wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 2005;78(1):19-24.

92. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Briggs Update 1999;12(3):17-19.

93. Klier CM, Schafer MR, Schmid-Siegel B, Lenz G, Mannel M. St. John's Wort (Hypericum Perforatum)—Is it safe during breastfeeding? Pharmacopsychiatry 2002;35:29-30.

94. Lee A, Minhas R, Ito S. Safety of St. John's Wort during breastfeeding. Am Soc Clin Pharmacol Ther 2000;130.

95. United States Pharmacopoeia (USP), ed. National Formulary, 18th edition, Supplement 9. Rockville: United States Pharmacopeial Convention, 1998.

96. Blumenthal M. St. John's wort. The complete German Commission E monographs. Austin: American Botanical Council, 1998.

0 0

Post a comment